Loading insider details...
Beta
Latest Form 4 (Jan 22, 2026): Grant/Award of 350,000 TCRX shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 22, 2026 | TScan Therapeutics, Inc. (TCRX) | Grant/Award | 350,000 | n/a |
| Feb 11, 2025 | TScan Therapeutics, Inc. (TCRX) | Grant/Award | 270,000 | n/a |
| Feb 2, 2024 | TScan Therapeutics, Inc. (TCRX) | Grant/Award | 750,000 | n/a |
| Nov 30, 2023 | Candel Therapeutics, Inc. (CADL) | Tax Withholding | 20,153 | $18.1K |
| Nov 28, 2023 | Candel Therapeutics, Inc. (CADL) | Grant/Award | 125,717 | n/a |
| May 2, 2023 | Candel Therapeutics, Inc. (CADL) | Grant/Award | 90,000 | n/a |
| Dec 12, 2022 | Candel Therapeutics, Inc. (CADL) | Purchase | 3,100 | $5.2K |
| Nov 30, 2022 | Candel Therapeutics, Inc. (CADL) | Grant/Award | 90,877 | n/a |
| Sep 23, 2022 | Candel Therapeutics, Inc. (CADL) | Grant/Award | 230,000 | n/a |
| Mar 3, 2020 | Akebia Therapeutics, Inc. (AKBA) | Grant/Award | 30,000 | n/a |